Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT06817720Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olverembatinib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year and Major Molecular Response at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06817720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06817720.